Full Press Release Details
Protalix BioTherapeutics to Present at the Oppenheimer Small and Mid Cap Clinical and Regulatory Conference
CARMIEL, Israel, July 31, 2008 (Business Wire) Protalix BioTherapeutics, Inc. (Amex: PLX),
announced today that it will present at the Oppenheimer Small and Mid Cap Clinical and Regulatory
Conference in New York City on August 4, 2008. The conference is being held at Oppenheimer s
offices located at 300 Madison Ave. Dr. David Aviezer, Protalix s President and Chief Executive
Officer will give a corporate overview at 9:30 AM ET and will participate on the Designing a
Pivotal Program with an Eye Towards Approval panel at 9:55 AM ET.
Webcasts of the corporate presentation and panel will be available on Protalix s website at
www.protalix.com under the events calendar section.
About Protalix BioTherapeutics
Protalix is a biopharmaceutical company. Its goal is to become a fully integrated
biopharmaceutical company focused on the development and commercialization of proprietary
recombinant therapeutic proteins to be expressed through its proprietary plant cell based
expression system. Protalix s ProCellEx(TM) presents a proprietary method for the expression of
recombinant proteins that Protalix believes is safe and scalable and will allow for the
cost-effective, industrial-scale production of recombinant therapeutic proteins. Protalix is
enrolling and treating patients in its pivotal phase III clinical trial in Israel, Europe the
United States and other locations for its lead product candidate, prGCD, for its enzyme replacement
therapy for Gaucher disease, a lysosomal storage disorder in humans, and has reached an agreement
with the United States Food and Drug Administration on the final design of the pivotal phase III
clinical trial through the FDA s Special Protocol Assessment (SPA) process. Protalix is also
advancing additional recombinant biopharmaceutical drug development programs.
The Trout Group, LLC
Marcy Strickler, 646-378-2927